The Association between Maternal Dietary Iron Intake during the First Trimester of Pregnancy with Pregnancy Outcomes and Pregnancy-Related Complications

The Effect of Nutrition Education Program on Overweight/Obese Patients with Non-Alcoholic Fatty Liver Disease: a Single-Blind Parallel Randomized Controlled Trial

The aim of this study was to assess the effects of a nutrition education program on overweight/obese patients with non-alcoholic fatty liver disease (NAFLD). This single-blind, parallel randomized controlled trial was conducted on 82 NAFLD patients (mean age 48.89 ± 9.85 years) in Isfahan, Iran. Patients were randomly allocated to receive nutrition education program combined with usual care or usual care alone for 2 months. Metabolic markers, including lipid profile, fasting blood glucose (FBG) and dietary intakes were obtained for each patient at baseline and at the end of the study. Nutrition education intervention resulted in a significant decrease compared with usual care in serum levels of total cholesterol (TC) and triglyceride (TG) (p 0.05). Furthermore, energy and sugar intakes of patients were reduced significantly in response to our intervention (p < 0.05). Nutrition education intervention significantly reduced serum levels of TC and TG but did not affect other metabolic markers including FBG, LDL-C, and HDL-C. Also, it could reduce total energy and sugar intake. Thus, this study could be useful to use this educational program for NAFLD patients in order to influence their metabolic markers and dietary intakes. TRIAL REGISTRATION: IRCT Identifier: IRCT2014101811763N17

Brewer's yeast improves glycemic indices in type 2 diabetes mellitus

Brewer's yeast may have beneficial effects on insulin receptors because of its glucose tolerance factor in diabetic patients. This study was conducted to investigate the effects of brewer's yeast supplementation on glycemic indices in patients with type 2 diabetes mellitus. In a randomized double blind controlled clinical trial, 84 adults [21 men and 63 women] aged 46.3 +/- 6.1 years old with type 2 diabetes mellitus were recruited and divided randomly into two groups: Supplement group receiving brewer's yeast [six 300mg tablets/day, total 1800 mg] and control group receiving placebo [six 300mg tablets/day] for 12 weeks. Body weight, height, body mass index, food consumption [based on 24h food record], fasting blood sugar [FBS], glycosylated hemoglobin, insulin sensitivity, and insulin resistance were measured before and after the intervention. Data analysis was performed using the Statistical Package for Social Sciences [version 18.0]. The changes in FBS, glycosylated hemoglobin, and insulin sensitivity were significantly different between the two groups during the study [respectively P < 0.001, P < 0.001, P = 0.02 independent sample t-test]. There was a significant difference in FBS, glycosylated hemoglobin, and insulin sensitivity at the end of the study between the two groups after removing the effects of baseline values [respectively P = 0.002, P < 0.001, P = 0.02, analysis of covariance]. Changes in body mass index, 24h food record, insulin resistance were not significant. Dietary supplementation with brewer's yeast besides the usual treatment of diabetes can ameliorate blood glucose variables in type 2 diabetes mellitus

effect of Omega-3 supplements on antioxidant capacity in patients with type 2 diabetes

Diabetes is one of the most common chronic diseases in which antioxidant capacity changes. Omega-3 fatty acids have extensive biological effects including their advantage on lipoprotein metabolism, platelet function, cytokine production, clotting, fibrinolysis, and inflammatory factors. This study aimed to investigate the effect of omega-3 fatty acid supplements on antioxidant capacity in patients with type 2 diabetes. This clinical trial enrolled 71 women with type 2 diabetes in two case [treated with omega-3 capsules] and control [treated with placebo] groups. In the first stage, participants filled out a demographics questionnaire including age, height, weight, waist circumference, and hip circumference. Their blood sample was taken to evaluate glycosylated hemoglobin and antioxidant capacity. Then the case group received intervention for 8 weeks and weight, waist circumference, and hip circumference were measured and a blood sample was taken again. The data were analyzed using SPSS 18 software. The mean difference of antioxidant capacity before and after intervention was significant [P < 0.001]. Antioxidant capacity increased in the case group and reduced in the control group. With regard to the results of the present study, patients with type 2 diabetes increase their antioxidant capacity, enhance their antioxidant defense system, and probably prevent diabetes complications and related disease progress by taking omega-3 supplements

Lipid profiles and serum Visfatin concentrations in patients with type II diabetes in comparison with healthy controls

Visfatin is a new adipocytokine which is largely secreted by visceral adipose tissue and its effects in the development of diabetes and inflammatory reactions are similar to insulin. It acts synergistically with insulin in increasing glucose cellular uptake, stimulating glucose transfer to the muscle and adipose tissue, as well as in preventing hepatic glucose production. Its insulin-like effects are mediated through direct connection and activation of insulin receptors without any change or competition with the insulin. This case-control study was conducted among 64 women consisting of 32 diabetic patients, and 32 age-matched healthy controls. The case group consisted of 32 post-menopausal diabetic women, aged 45-65 years. Those patients were eligible who had a history of at least five years of type II diabetes, without any complications of diabetes, and who were treated only by oral glucose-lowering medications. Those individuals with C-reactive protein [CRP] test of 3+ and above were excluded from the study. Results were compared with age- and sex- matched controls. Average visfatin level was significantly higher in diabetic patients than in controls [4.3 +/- 1.06ng/dl vs. 3.15 +/- 0.74ng/dl, respectively< 0.001]. The mean values of anthropometric indexes and lipid profile were not significantly different between diabetic patients and controls. This study documented an inverse relationship between circulating level of visfatin and fasting blood glucose. This finding may suggest the role of increased visfatin level and increase in synthesis and secretion of the cytokines from adipocytes. These findings may be useful for primary and secondary preventive issues in diabetic and pre-diabetic individuals